Ribonucleic Acid (RNA) Methylation Sequencing Market Report 2026

Ribonucleic Acid (RNA) Methylation Sequencing Market Report 2026 Market Overview

• Ribonucleic Acid (RNA) Methylation Sequencing Market Report 2026 market size has reached to $0.66 billion in 2025 • Expected to grow to $1.34 billion in 2030 at a compound annual growth rate (CAGR) of 15% • Growth Driver: Increasing Demand For Precision Medicine Driving The Market Growth Due To Patient-Specific Treatment Planning • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ribonucleic Acid (RNA) Methylation Sequencing Market?

Ribonucleic acid (RNA) methylation sequencing is a high-throughput molecular biology technique used to identify, map, and quantify chemical modifications on RNA molecules, particularly methylation marks such as N6-methyladenosine (m6A). It enables comprehensive analysis of epitranscriptomic regulation by capturing modification patterns across transcriptomes, supporting insights into gene expression control, RNA stability, and cellular function. The technique relies on advanced sequencing platforms, chemical enrichment methods, and bioinformatics tools to generate high-resolution modification profiles. The main product types of ribonucleic acid (RNA) methylation sequencing include reagents, sequencing platforms, and software. Reagents refer to specialized materials and chemical components used in RNA methylation sequencing workflows for sample preparation and analysis. These products use technologies such as bisulfite sequencing, methylated ribonucleic acid immunoprecipitation sequencing, nanopore sequencing, and other technologies. The key applications of cancer research, genetic research, drug discovery, and agricultural biotechnology, while the end-users academic and research institutes, pharmaceutical and biotechnology companies, and others.

What Is The Ribonucleic Acid (RNA) Methylation Sequencing Market Growth Forecast?

The ribonucleic acid (RNA) methylation sequencing market size is expected to see rapid growth in the next few years. It will grow to $1.34 billion in 2030 at a compound annual growth rate (CAGR) of 15.0%. The growth in the forecast period can be attributed to integration of AI based methylation calling and sequence analysis tools, rising demand for precision medicine driven epitranscriptomic profiling, expansion of single molecule and long read sequencing technologies, increasing application of rna methylation in drug discovery and therapeutic targeting, growth in cloud enabled multi omics data integration platforms. Major trends in the forecast period include advancement of nanopore based direct rna methylation sequencing for real time epitranscriptomic profiling, increasing adoption of m6a immunoprecipitation sequencing for cancer biomarker discovery, integration of AI driven bioinformatics pipelines for rna modification detection, growing use of high throughput sequencing platforms for transcriptome wide methylation mapping, expansion of cloud based methylation data analytics for large scale genomic studies.

What Are The Drivers Of The Ribonucleic Acid (RNA) Methylation Sequencing Market?

The increasing demand for precision medicine is expected to propel the growth of the ribonucleic acid (RNA) methylation sequencing market going forward. Precision medicine refers to a medical approach that tailor’s treatment and prevention strategies to an individual’s unique genetic makeup, environment, and lifestyle. The demand for precision medicine is rising due to advancements in genomics allow doctors to understand a patient’s genetic profile, enabling more targeted and effective treatments. Ribonucleic acid (RNA) methylation sequencing enables precision medicine through high-resolution mapping of RNA modifications that reveal disease-specific signatures for improved diagnosis, patient stratification, and targeted therapy development. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, personalized therapies saw significant growth, with the FDA approving 16 new treatments for rare diseases in 2023 compared to six approvals in 2022. Therefore, the increasing demand for precision medicine is driving the growth of ribonucleic acid (RNA) methylation sequencing industry. The rising prevalence of cancer is expected to propel the growth of the ribonucleic acid (RNA) methylation sequencing market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body, which can form tumors and interfere with normal bodily functions. The prevalence of cancer is growing due to the aging population, as older individuals have a higher likelihood of accumulating genetic mutations that can trigger uncontrolled cell growth. Ribonucleic acid (RNA) methylation sequencing enables cancer research and treatment by precisely mapping RNA modification patterns that influence tumor development, progression, and drug response, improving biomarker discovery, early detection, prognosis assessment, and targeted therapy design. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the rising prevalence of cancer is driving the growth of the ribonucleic acid (RNA) methylation sequencing industry. The rising pharmaceutical research and development (R&D) expenditure is expected to propel the growth of the ribonucleic acid (RNA) methylation sequencing market going forward. Pharmaceutical R&D expenditure refers to the total investment made by pharmaceutical and biomedical organizations in discovering, developing, and testing new drugs, therapies, and biotechnology solutions. Pharmaceutical research and development (R&D) expenditure is growing due to the increasing demand for innovative therapies to treat complex, chronic, and previously hard-to-treat diseases, which requires continuous investment in advanced drug discovery and biotechnology research. Pharmaceutical research and development (R&D) expenditure supports ribonucleic acid (RNA) methylation sequencing by driving increased funding for advanced molecular research, which facilitates the adoption of high-throughput sequencing technologies to analyze RNA modifications more precisely, improve understanding of disease biology, and accelerate the development of targeted and personalized therapeutic solutions. For instance, in December 2024, according to the Office for National Statistics, a UK-based government agency, in 2023, UK businesses invested $64.73 billion (£50.0 billion) in research and development (R&D), reflecting a $1.83 billion (£1.4 billion) or 2.9% increase compared to 2022. Therefore, the rising pharmaceutical research and development (R&D) expenditure is driving the growth of the ribonucleic acid (RNA) methylation sequencing industry.

Key Players In The Global Ribonucleic Acid (RNA) Methylation Sequencing Market

Major companies operating in the ribonucleic acid (RNA) methylation sequencing market report are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., QIAGEN N.V., BGI Genomics Co. Ltd., Novogene Co. Ltd., Takara Bio Inc., Oxford Nanopore Technologies plc, Zymo Research Corp., CD Genomics LLC, Alida Biosciences Inc., Arraystar Inc., DirectSeq Bioscience, GenXPro GmbH, LC Sciences LLC, SeqMatic LLC, Illumina Inc., Pacific Biosciences of California Inc., New England Biolabs Inc., Diagenode SA, EpiGentek Group Inc.

What Defines the Ribonucleic Acid (RNA) Methylation Sequencing Market?

The ribonucleic acid (RNA) methylation sequencing market consists of revenues earned by entities by providing services such as RNA sample preparation, methylated RNA enrichment, sequencing library construction, high-throughput sequencing, bioinformatics analysis, data interpretation, and assay development for epitranscriptomic studies. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribonucleic acid (RNA) methylation sequencing market also includes sales of sequencing kits, RNA extraction kits, methylation-specific antibodies, library preparation kits, and sequencing consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ribonucleic Acid (RNA) Methylation Sequencing Market Report 2026?

The ribonucleic acid (rna) methylation sequencing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid (rna) methylation sequencing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.